Acurx Pharmaceuticals, Inc. (ACXP) News

Acurx Pharmaceuticals, Inc. (ACXP): $3.75

-0.04 (-1.06%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ACXP to Watchlist
Sign Up

Industry: Biotech


Ranked

of NR

in industry

Filter ACXP News Items

ACXP News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ACXP News From Around the Web

Below are the latest news stories about Acurx Pharmaceuticals Inc that investors may wish to consider to help them evaluate ACXP as an investment opportunity.

Maxim Group Thinks Acurx Pharmaceuticals’ Stock is Going to Recover

Maxim Group analyst Jason McCarthy reiterated a Buy rating on Acurx Pharmaceuticals (ACXP – Research Report) yesterday and set a price target of $12.00. The company's shares closed last Tuesday at $4.38, close to its 52-week low of $3.71. According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -10.7% and a 21.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics. Currently, the analyst consensus on Acurx Pharmaceuticals is a Moderate Buy with an average price target of $12.00.

Brian Anderson on TipRanks | December 21, 2021

Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI)

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the first patient has been enrolled in its Phase 2b clinical trial of ibezapolstat, its lead antibiotic candidate, against the standard of care to treat CDI, vancomycin, in a 64 patient double-blind randomized trial expected to be completed mid-2022. C. difficile bacteria remains o

Yahoo | December 6, 2021

Acurx Pharmaceuticals (NASDAQ:ACXP) Coverage Initiated at Maxim Group

Maxim Group started coverage on shares of Acurx Pharmaceuticals (NASDAQ:ACXP) in a research note issued to investors on Monday morning, The Fly reports. The brokerage issued a buy rating and a $12.00 target price on the stock. Acurx Pharmaceuticals stock opened at $4.22 on Monday. The businesss 50-day simple moving average is $4.91. Acurx Pharmaceuticals []

Transcript Daily | December 3, 2021

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Director Buys $24,979.24 in Stock

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Director Carl Sailer acquired 5,161 shares of the firm’s stock in a transaction on Tuesday, November 23rd. The stock was purchased at an average price of $4.84 per share, for a total transaction of $24,979.24. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is […]

Dakota Financial News | November 25, 2021

David P. Luci Buys 5,200 Shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Stock

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) CEO David P. Luci bought 5,200 shares of the firms stock in a transaction that occurred on Friday, November 19th. The shares were purchased at an average cost of $4.80 per share, for a total transaction of $24,960.00. The transaction was disclosed in a legal filing with the SEC, which is []

Transcript Daily | November 24, 2021

Short Interest in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Increases By 17.7%

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) saw a large increase in short interest in the month of October. As of October 29th, there was short interest totalling 119,800 shares, an increase of 17.7% from the October 14th total of 101,800 shares. Based on an average daily volume of 72,400 shares, the days-to-cover ratio is currently 1.7 days. […]

Transcript Daily | November 23, 2021

Acurx Pharmaceuticals, Inc. (ACXP) CEO David Luci on Q3 2021 Earnings Call Transcript

No summary available.

Seeking Alpha | November 15, 2021

Acurx Pharmaceuticals reports Q3 results

No summary available.

Seeking Alpha | November 15, 2021

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2021 Results and Provides Business Update

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the quarter ended September 30, 2021.

Yahoo | November 12, 2021

Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that new microbiome data from its Phase 2a clinical trial for C. difficile Infection (CDI) were presented at the 9th International C. diff Conference & Health Expo entitled: "Can Emerging Microbiome Findings Contribute to CDI Anti-Recurrence Effect?" The presentation was made on Novembe

Yahoo | November 8, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4226 seconds.